A carregar...
A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort
INTRODUCTION: Ruxolitinib has been approved for the treatment of myelofibrosis (MF). In this study, we present safety and efficacy findings from an analysis of 104 patients with intermediate- and high-risk MF in a Brazilian cohort of the JUMP study who received treatment with ruxolitinib. METHODS: J...
Na minha lista:
| Publicado no: | Hematol Transfus Cell Ther |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Sociedade Brasileira de Hematologia e Hemoterapia
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7031100/ https://ncbi.nlm.nih.gov/pubmed/31235325 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.htct.2019.01.009 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|